

Viktor Soukup

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/150078/viktor-soukup-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

37
papers

3,110
citations

20
h-index

42
g-index

42
ext. papers

4,356
ext. citations

4.6
avg, IF

4.87
L-index

#	Paper	IF	Citations
37	Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria.. <i>European Urology</i> , 2022 ,	10.2	2
36	European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. <i>European Urology</i> , 2021 , 79, 480-488	10.2	51
35	Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. <i>European Urology Oncology</i> , 2021 , 4, 182-191	6.7	15
34	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. <i>European Urology</i> , 2021 , 79, 62-79	10.2	176
33	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). <i>European Urology</i> , 2021 ,	10.2	51
32	Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 440-448	2.8	14
31	Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel. <i>European Urology Focus</i> , 2020 , 6, 479-489	5.1	39
30	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. <i>European Urology</i> , 2019 , 76, 639-657	10.2	531
29	Prevention of bladder cancer incidence and recurrence: tobacco use. <i>Current Opinion in Urology</i> , 2018 , 28, 80-87	2.8	15
28	Gene Expression Analysis of Immunomagnetically Enriched Circulating Tumor Cell Fraction in Castration-Resistant Prostate Cancer. <i>Molecular Diagnosis and Therapy</i> , 2018 , 22, 381-390	4.5	3
27	Placental Growth Factor in Bladder Cancer Compared to the Diagnostic Accuracy and Prognostic Performance of Vascular Endothelial Growth Factor A. <i>Anticancer Research</i> , 2018 , 38, 239-246	2.3	7
26	Indication for a Single Postoperative Instillation of Chemotherapy in Non-muscle-invasive Bladder Cancer: What Factors Should Be Considered?. <i>European Urology Focus</i> , 2018 , 4, 525-528	5.1	4
25	EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. <i>European Urology</i> , 2017 , 71, 447-461	10.2	1199
24	Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. <i>European Urology</i> , 2017 , 72, 801-813	10.2	124
23	PD48-03 RISK FACTORS FOR RESIDUAL DISEASE AT RE-TUR IN T1G3 BLADDER CANCER. <i>Journal of Urology</i> , 2017 , 197,	2.5	2
22	Prognostic Importance of Vitamins A, E and Retinol-binding Protein 4 in Renal Cell Carcinoma Patients. <i>Anticancer Research</i> , 2017 , 37, 3801-3806	2.3	6
21	Urinary Cell-Free DNA Quantification as Non-Invasive Biomarker in Patients with Bladder Cancer. <i>Urologia Internationalis</i> , 2016 , 96, 25-31	1.9	26

20	Comparison of MicroRNA Content in Plasma and Urine Indicates the Existence of a Transrenal Passage of Selected MicroRNAs. <i>Advances in Experimental Medicine and Biology</i> , 2016 , 924, 97-100	3.6	4
19	MicroRNAs in urine supernatant as potential non-invasive markers for bladder cancer detection. <i>Neoplasma</i> , 2016 , 63, 799-808	3.3	40
18	The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guërin. <i>BJU International</i> , 2016 , 118, 44-52	5.6	72
17	Prognosis of Castration-resistant Prostate Cancer Patients - Use of the AdnaTest [®] System for Detection of Circulating Tumor Cells. <i>Anticancer Research</i> , 2016 , 36, 2019-26	2.3	9
16	Panel of Urinary Diagnostic Markers for Non-Invasive Detection of Primary and Recurrent Urothelial Urinary Bladder Carcinoma. <i>Urologia Internationalis</i> , 2015 , 95, 56-64	1.9	29
15	Diagnostic Importance of Selected Protein Serum Markers in the Primary Diagnostics of Prostate Cancer. <i>Urologia Internationalis</i> , 2015 , 95, 429-35	1.9	10
14	Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guërin: results of a retrospective multicenter study of 2451 patients. <i>European Urology</i> , 2015 , 67, 74-82	10.2	149
13	The prognostic value of T1 bladder cancer substaging: a single institution retrospective study. <i>Urologia Internationalis</i> , 2014 , 92, 150-6	1.9	23
12	Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. <i>BJU International</i> , 2013 , 111, E30-6	5.6	60
11	Prediction of recurrence in low and intermediate risk non-muscle invasive bladder cancer by real-time quantitative PCR analysis: cDNA microarray results. <i>Neoplasma</i> , 2013 , 60, 295-301	3.3	21
10	Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. <i>European Urology</i> , 2012 , 62, 290-302	10.2	84
9	Narrow band imaging cystoscopy improves the detection of non-muscle-invasive bladder cancer. <i>Urology</i> , 2010 , 76, 658-63	1.6	112
8	Primary large cell neuroendocrine carcinoma of the kidney. <i>Pathology and Oncology Research</i> , 2010 , 16, 139-42	2.6	7
7	Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pT ₁ bladder urothelial carcinoma. <i>Urology</i> , 2008 , 71, 718-22	1.6	47
6	Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?. <i>Urologia Internationalis</i> , 2008 , 80, 413-8	1.9	24
5	Anaplastic variant of spermatocytic seminoma. <i>Pathology Research and Practice</i> , 2007 , 203, 621-4	3.4	15
4	Pigmented microcystic chromophobe renal cell carcinoma. <i>Pathology Research and Practice</i> , 2007 , 203, 593-7	3.4	12
3	Analysis of genetic events in 17p13 and 9p21 regions supports predominant monoclonal origin of multifocal and recurrent bladder cancer. <i>Cancer Letters</i> , 2006 , 242, 68-76	9.9	12

2	Association of PAX5 expression with clinical outcome in patients with TaT1 transitional cell carcinoma of the bladder. <i>Urology</i> , 2006 , 67, 756-61	1.6	12
1	5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. <i>BJU International</i> , 2005 , 96, 798-802	5.6	103